A selective histone deacetylase inhibitor for myeloma

被引：0
|
作者：
Pratt, Guy [1 ]
机构：
[1] Univ Hosp Birmingham NHS Fdn Trust, Birmingham B15 2WB, W Midlands, England
来源：
LANCET ONCOLOGY | 2016年 / 17卷 / 11期
关键词：
PANOBINOSTAT PLUS BORTEZOMIB; MULTIPLE-MYELOMA; DEXAMETHASONE;
D O I：
10.1016/S1470-2045(16)30407-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1472 / 1474
页数：4
相关论文
共 50 条
  • [1] Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy
    He, Yanjuan
    Jiang, Duanfeng
    Zhang, Kaixuan
    Zhu, Yinghong
    Zhang, Jingyu
    Wu, Xuan
    Xia, Jiliang
    Zhu, Yan
    Zou, Lang
    Hu, Jian
    Cui, Yajuan
    Zhou, Wen
    Chen, Fangping
    JOURNAL OF CANCER, 2021, 12 (20): : 6198 - 6208
  • [2] Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma
    Imai, Yoichi
    Ohta, Eri
    Takeda, Shu
    Sunamura, Satoko
    Ishibashi, Mariko
    Tamura, Hideto
    Wang, Yan-hua
    Deguchi, Atsuko
    Tanaka, Junji
    Maru, Yoshiro
    Motoji, Toshiko
    JCI INSIGHT, 2016, 1 (05):
  • [3] Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma
    Wahaib, Kristy
    Beggs, Ashton E.
    Campbell, Hope
    Kodali, Leela
    Ford, Patrick D.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (07) : 441 - 450
  • [4] Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Vogl, Dan T.
    Raje, Noopur
    Jagannath, Sundar
    Richardson, Paul
    Hari, Parameswaran
    Orlowski, Robert
    Supko, Jeffrey G.
    Tamang, David
    Yang, Min
    Jones, Simon S.
    Wheeler, Catherine
    Markelewicz, Robert J.
    Lonial, Sagar
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3307 - 3315
  • [5] Discovery and development of Santacruzamate A, a potent and selective histone deacetylase inhibitor
    Balunas, M. J.
    Pavlik, C. M.
    Wong, C. Y. B.
    Lopez, D. D.
    Engene, N.
    McPhail, K.
    Gerwick, W. H.
    PLANTA MEDICA, 2012, 78 (11) : 1050 - 1050
  • [6] Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
    He, Jingsong
    Chen, Qingxiao
    Gu, Huiyao
    Chen, Jing
    Zhang, Enfan
    Guo, Xing
    Huang, Xi
    Yan, Haimeng
    He, DongHua
    Yang, Yang
    Zhao, Yi
    Wang, Gang
    He, Huang
    Yi, Qing
    Cai, Zhen
    HAEMATOLOGICA, 2018, 103 (08) : 1369 - 1379
  • [7] Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
    Sager, Philip T.
    Balser, Barbara
    Wolfson, Julie
    Nichols, Jean
    Pilot, Richard
    Jones, Suzanne
    Burris, Howard A.
    CANCER MEDICINE, 2015, 4 (08): : 1178 - 1185
  • [8] Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor
    Porter, Nicholas J.
    Shen, Sida
    Barinka, Cyril
    Kozikowski, Alan P.
    Christianson, David W.
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (12): : 1301 - 1305
  • [9] Targeting Histone Deacetylase 11 with a Highly Selective Inhibitor for the Treatment of MASLD
    Zhang, Feng
    Yue, Kairui
    Sun, Simin
    Lu, Shengyuan
    Jia, Geng
    Zha, Yang
    Zhang, Shuang
    Chou, C. James
    Liao, Chenzhong
    Li, Xiaoyang
    Duan, Yajun
    ADVANCED SCIENCE, 2025,
  • [10] Histone deacetylase inhibitors in multiple myeloma
    Deleu, Sarah
    Menu, Eline
    Van Valckenborgh, Els
    Van Camp, Ben
    Fraczek, Joanna
    Broek, Isabelle Vande
    Rogiers, Vera
    Vanderkerken, Karin
    HEMATOLOGY REPORTS, 2009, 1 (01) : 46 - 55
12345